Skip to main content

EndoStim's neurostimulation therapy for GERD receives permanent reimbursement coverage in Germany

NIJMEGEN, Netherlands, Oct. 13, 2015 /PRNewswire/ — EndoStim, a medical device company developing neurostimulation therapy for gastroesophageal reflux disease (GERD), announced today that InEK, the German Institute for the Hospital Remuneration System, has decided to approve the request of DGVS (German Society for Digestive and Metabolic Diseases) and assign a permanent DRG (Diagnosis Related Group)1 code covering reimbursement for EndoStim therapy to treat GERD in Germany.2
http://www.prnewswire.com/news-releases/endostims-neurostimulation-therapy-for-gerd-receives-permanent-reimbursement-coverage-in-germany-300158730.html

No Comments yet!

Your Email address will not be published.

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2022 Esophageal Cancer Education Foundation- by domino